This summer more than 100 select Arizona youth participated in unique summer programs at the University of Arizona College of Medicine – Phoenix. Opportunities such as the college’s Department of Basic Medical Sciences’ High School Research Internship program and Summer Scrubs provided local adolescents with the chance to work alongside biomedical experts and develop greater interest in pursuing a future career in health care.Continue reading
Category Archives: AZBio News
CEI Develops Start Up Lifecycle Resource Kit
The FREE “Start Up Lifecycle” Resource Kit includes an e-book that compiles the complete online blog series PLUS a previously unpublished resource guide; the full Startup Lifecycle presentation from leading experts in each stage of development; and access to the never-before-seen recorded workshop from June 2015.Continue reading
Paradigm and TME Research To Launch Precision Medicine Breast Cancer Registry
Paradigm and TME Research today announced the launch of a precision medicine breast cancer registry.Continue reading
HTG Enters Worldwide Innovative Networking (WIN) Consortium for Personalized Cancer Medicine
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications announced it has joined the Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine as an official technology partner.
CTX Acquires Promising Proprietary Drug Delivery Assets
CTX Technology Inc., based in Tucson, Arizona, has acquired the intellectual property, formulations and related data of Convoy Therapeutics Inc.
ULTHERA ANNOUNCES TWO YEAR FDA CLEARANCE FOR CELLFINA™ SYSTEM
Cellfina™ Earns Longest FDA Clearance for a Cellulite Treatment
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms
Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its pharmaceutical cannabidiol (CBD) candidate for the treatment of infantile spasms (IS).Continue reading
Helios Scholars at TGen graduate from summer biomedical research training program
45 students from across Arizona featured at symposium sponsored by Helios Education FoundationContinue reading
CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia
The Clinical Data Interchange Standards Consortium (CDISC), the Critical Path Institute (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that data standards for clinical research in the areas of Schizophrenia, Hepatitis C and Dyslipidemia have been published for use on the CDISC website. These three Therapeutic Area (TA) standards were developed per the CDISC global, consensus-based Standards Development Process through the collaborative Coalition for Accelerating Standards and Therapies (CFAST) Initiative, a partnership of CDISC and C-Path.